- Home
- DIAX vs BME Comparison
DIAX vs BME Comparison
Compare DIAX & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | DIAX | BME |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Trusts Except Educational Religious and Charitable |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.9M | 547.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | DIAX | BME |
|---|---|---|
| Price | $14.49 | $39.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 130.1K | 36.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.42 | $34.18 |
| 52 Week High | $15.85 | $42.74 |
Technical Indicators
Market Signals| Indicator | DIAX | BME |
|---|---|---|
| Relative Strength Index (RSI) | 24.14 | 22.68 |
| Support Level | $14.49 | $35.48 |
| Resistance Level | $14.97 | $42.55 |
| Average True Range (ATR) | 0.21 | 0.59 |
| MACD | -0.08 | -0.26 |
| Stochastic Oscillator | 2.20 | 0.00 |
Price Performance
Historical ComparisonAbout DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.